第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。
编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。）
Poster Session 4
日期：12月12日
时间：5:30～7:00 p.m.
地点：Halls 2-3
P4-01-18:NEDD9 expression as an indicator for pathological complete response(pCR)in early-stage HER2-positive breast cancer patients undergoing neoadjuvant therapy
NEDD9表达作为接受新辅助治疗的早期HER2阳性乳腺癌患者病理完全缓解（pCR）的指标
报告作者：Bei Jiang
P4-01-23:Potential prognostic Value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer
HER2/CEP17 FISH比值在HER2阳性非转移性乳腺癌中的潜在预后价值
报告作者：Fangchao Zheng
P4-01-30:Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment
HER2阳性乳腺癌的蛋白质基因组特征及其对新辅助抗HER2治疗的反应
报告作者：Kang Wang
P4-02-20:Investigating Age-Dependent Breast Cancer Dynamics in a Mouse Model
在小鼠模型中研究年龄依赖性乳腺癌动力学
报告作者：Yun Zhang
P4-02-25:Dietary-Restriction Genes as Modulators of Breast Cancer Risk Through Metabolic Pathways
饮食限制基因通过代谢途径调节乳腺癌风险
报告作者：Yiyin Zhang
P4-03-08:Pre-and post-diagnostic healthy lifestyle and cardiovascular disease among breast cancer survivors
乳腺癌幸存者诊断前后的健康生活方式和心血管疾病
报告作者：Qiang Liu
P4-03-15:Clinical characterization of taxanes chemotherapeutic regiments-induced peripheral neurotoxicity and establishment of a risk model
紫杉类药物化疗方案诱导的周围神经毒性的临床特征和风险模型的建立
报告作者：Bin Yang
P4-03-22:Inhibiting JNK signaling enhances the antitumor efficacy of macrophage-targeting agents in triple-negative breast cancer by inducing an immunoactive tumor microenvironment
抑制JNK信号通路可通过诱导免疫活性肿瘤微环境增强巨噬细胞靶向药物在三阴性乳腺癌中的抗肿瘤疗效
报告作者：Xuemei Xie
P4-03-30:GPR56/ADGRG1 promotes the progression of triplenegative breast cancer by enhancing PKM2/LDH-mediated glycolysis via the PI3K/AKT/mTOR/HIF-1αpathway
GPR56/ADGRG1通过PI3K/AKT/mTOR/HIF-1α通路增强PKM2/ldh介导的糖酵解促进三阴性乳腺癌的进展
报告作者：Haizhu Chen
P4-04-21:Frozen gloves can prevent chemotherapy-induced nail pigmentation of the hand in early-stage breast cancer patients:a prospective self-matched case-control study
冷冻手套可预防早期乳腺癌患者化疗引起的手部指甲色素沉着：一项前瞻性自身匹配病例对照研究
报告作者：Fei Xu
P4-04-23:Reverse-sequence Endoscopic Versus Conventional Open Nipple-Sparing Mastectomy with Implant-based Breast Reconstruction:A Single-center Prospective Cohort Study(RECO study)
腔镜与传统开放保留乳头乳晕的乳房切除术后假体乳房重建的单中心前瞻性队列研究（RECO研究）
报告作者：Tianyuan Li
P4-04-26:A New Option for post-CDK4/6is Resistance Era:Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6 Inhibitors
后CDK4/6抑制剂耐药时代的新选择：基于安罗替尼的联合治疗在CDK4/6抑制剂耐药的激素受体阳性转移性乳腺癌中的多中心真实世界研究
报告作者：Quchang Ouyang
P4-04-31:A phase Ib/II study of PARPi Mefuparib Hydrochloride(CVL218)in combination with PD-1 inhibitor plus chemotherapy in metastatic or recurrent triple-negative breast cancer(TNBC)
一项关于PARP抑制剂盐酸美呋哌瑞（CVL218）联合PD-1抑制剂加化疗用于转移性或复发性三阴性乳腺癌（TNBC）的Ib/I期研究
报告作者：Jian Zhang
P4-04-32:Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
99mTc-利妥昔单抗联合染料双示法治疗乳腺癌新辅助化疗后腋窝前哨淋巴结活检的临床研究
报告作者：Hui Zhang
P4-04-35:Thioredoxin-Interacting Protein(TXNIP)as a Key Regulator of Tumor Growth and Progression
硫氧还蛋白相互作用蛋白（TXNIP）作为肿瘤生长和进展的关键调节因子
报告作者：Liang Liu
P4-04-37:SS Induces BRCA1 Reduction and Sensitizes Breast Cancer Cells to PARP Inhibitor Therapy
SS诱导BRCA1减少并使乳腺癌细胞对PARP抑制剂治疗敏感
报告作者：Jiaqi Chen
P4-04-41:The impacts of neoadjuvant or adjuvant chemotherapy on surgical complications and cosmetic outcomes of reverse-sequence endoscopic nipplesparing-mastectomy with immediate breast reconstruction.
新辅助或辅助化疗对反向序列内镜乳头保留乳房切除术联合即刻乳房重建术的手术并发症和美容效果的影响
报告作者：Kawun Chung
P4-04-42:A novel 3D-printed scaffold for patient-specific partial breast reconstruction:A Prospective，Single-Arm Clinical Trial
一种针对患者个体化部分乳房重建的新型3D打印支架：一项前瞻性单臂临床试验
报告作者：Juliang Zhang
P4-05-20:Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer
开发和验证用于预测乳腺癌新辅助全身治疗后腋窝状态的超声-病理联合模型
报告作者：Jue Wang
P4-05-21:Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapy
ctDNA动态追踪可对接受新辅助化疗的早期三阴性乳腺癌患者个体复发风险进行分层
报告作者：Qiang Liu
P4-07-16:First line CDK4/6 inhibitors plus endocrine therapy versus chemotherapy for HR+/HER2-metastatic breast cancer patients in real world:a multicenter YOUNGBC-30 study.
真实世界中HR+/HER2-转移性乳腺癌患者一线CDK4/6抑制剂联合内分泌治疗与化疗的比较：多中心YOUNGBC-30研究
报告作者：Biyun Wang
P4-08-08:Real-world data on cyclin-dependent kinase 4/6 inhibitor switching in patients with first-line hormone receptorpositive，HER2-negative metastatic breast cancer
一线激素受体阳性、HER2阴性转移性乳腺癌患者CDK4/6抑制剂转换的真实世界数据
报告作者：Lu Chen
P4-08-11:Linc01588-V4 is UPR-downregulated lncRNA in a PERK-dependent manner and estrogen-responsive gene mediated cell proliferation and migration of ER+breast cancer cells
Linc01588-V4是一种PERK依赖性方式下被未折叠蛋白反应（UPR）下调的长链非编码RNA（lncRNA），雌激素反应基因介导ER+乳腺癌细胞的增殖和迁移
报告作者：Wen Liu
P4-08-26:Trial in progress:First-in-human phase 1a/1b，doseescalation/expansion study of BGB-43395(CDK4 selective inhibitor)as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2-breast cancer&other advanced solid tumors
正在进行的试验：BGB-43395（CDK4选择性抑制剂）作为单药或联合治疗在中国HR+/HER2-乳腺癌和其他晚期实体瘤患者中的首次人类1a/1b期剂量递增/扩展研究
报告作者：Jian Zhang
P4-09-01:Contrast-enhanced ultrasound traced secondary sentinel lymph nodes in early-stage breast cancer to streamline sentinel lymph node biopsy----a preliminary study
应用超声造影追踪早期乳腺癌次级前哨淋巴结以简化前哨淋巴结活检——初步研究
报告作者：Xiaoling Liu
P4-09-02:Multiparametric MRI and Transfer Learning for Predicting Positive Margins in Breast-Conserving Surgery:A Multi-Center Study
多参数MRI和迁移学习预测保乳手术切缘阳性：一项多中心研究
报告作者：Xue Zhao
P4-09-27:The clinical benefits of CDK 4/6 inhibitors and biomarker interactions on HR+/HER2-advanced breast cancer patients:an updated pairwise meta-analysis of randomized controlled trials and network meta-analysis
CDK4/6抑制剂和生物标志物相互作用对HR+/HER2-晚期乳腺癌患者的临床获益：随机对照研究和网络荟萃分析的更新配对荟萃分析
报告作者：Sheng-Fan Wang
P4-10-07:Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment
在肝功能损害参与者中评价免疫抑制剂的药代动力学和安全性
报告作者：Xuejing Wang
P4-11-06:Neoadjuvant anlotinib plus nab-paclitaxel based chemotherapy in patients with HER2-negative breast cancer:A prospective，single-arm，single-center，phaseⅡclinical study
安罗替尼联合白蛋白结合型紫杉醇为基础的化疗用于HER2阴性乳腺癌患者的新辅助治疗：一项前瞻性、单臂、单中心、期Ⅱ临床研究
报告作者：Huimin Meng
P4-12-11:Large Oncosomes Loaded with circPEX13 Enhance Osteoclast Differentiation and Facilitate Breast Cancer Bone Metastasis
携带circPEX13的大型癌源外泌体促进破骨细胞分化并促进乳腺癌骨转移
报告作者：Jinpeng Luo
P4-12-14:Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapies in elderly HR+/HER2-metastatic or advanced breast cancer:patient-level network meta-analysis
CDK4/6抑制剂联合内分泌疗法治疗老年HR+/HER2-转移性或晚期乳腺癌的最新疗效和安全性：患者水平的网状荟萃分析
报告作者：Yun-Sheng Tai
P4-12-21:Efficacy and Safety of MRG002 in Prior TKI-Treated HER2 Positive Breast Cancer Patients:A Single Arm，Open Label，Multicenter，Phase II Study
MRG002在既往接受过TKI治疗的HER2阳性乳腺癌患者中的疗效和安全性：一项单臂、开放标签、多中心、II期研究
报告作者：Qiang Liu
P4-12-27:Exploring Stimulation Response of Cisplatin Prodrugs and Integrating Photothermal-Photoacoustic DualModal Theranostics in Triple-Negative Breast Cancer through Ozone-mediated Photothermal Catalytic Nanosystem
通过臭氧介导的光热催化纳米系统探索顺铂前体药物的刺激反应和整合光热-光声双模态诊疗治疗三阴性乳腺癌
报告作者：Dan Zheng
京公网安备 11010502033352号